EUVIMEDEUVIMED entdecken
Crossref

Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma

Haotian Qin, Qichang Wang, Juan Xu, Hui Zeng, Jixian Liu, Fei Yu, Jun Yang

International Immunopharmacology · 2024-12 · 143 · 113282

DOI: 10.1016/j.intimp.2024.113282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Haotian Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: National & Local Joint Engineering Research Center of Orthopaedic Biomaterials, Peking University Shenzhen Hospital, Shenzhen 518036, China; Shenzhen…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Anoikis, Gene Expression Regulation, Neoplastic, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anoikis, a form of programmed cell death induced by loss of cell contact, is closely associated with tumor invasion and metastasis, making it highly significant in lung cancer research. We examined the expression patterns and prognostic relevance of Anoikis-related genes (ARGs) in lung adenocarcinoma (LUAD) using the TCGA-LUAD database. This study identified molecular subtypes associated with Anoikis in LUAD and conducted functional enrichment analyses. We constructed an ARG risk score using univariate least absolute shrinkage and selection operator (LASSO) Cox regression, validated externally with GEO datasets and clinical samples. The clinical applicability of the prognostic model was evaluated using nomograms, calibration curves, decision curve analysis (DCA), and time-dependent AUC assessments. We identified four prognostically significant genes (PLK1, SLC2A1, CDKN3, PHLDA2) and two ARG-related molecular subtypes. ARGs were generally upregulated in LUAD and correlated with multiple pathways including the cell cycle and DNA replication. The prognostic model indicated that the low-risk group had better outcomes and significant correlations with clinicopathological features, tumor microenvironment, immune therapy responses, drug sensitivity, and pan-RNA epigenetic modification-related genes. Patients with low-risk LUAD were potential beneficiaries of immune checkpoint inhibitor (ICI) therapy. Prognostic ARGs' distribution and expression across various immune cell types were further analyzed using single-cell RNA sequencing. The pivotal role of CDKN3 in LUAD was confirmed through qRT-PCR and gene knockout experiments, demonstrating that CDKN3 knockdown inhibits tumor cell proliferation, migration, and invasion. Additionally, we constructed a ceRNA network involving CDKN3/hsa-miR-26a-5p/SNHG6, LINC00665, DUXAP8, and SLC2A1/hsa-miR-218-5p/RNASEH1-AS1, providing new insights for personalized and immune therapy decisions in LUAD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungAnoikisGene Expression Regulation, NeoplasticImmunotherapyLung NeoplasmsHumansBiomarkers, TumorCell Line, TumorDatabases, GeneticImmune Checkpoint InhibitorsNomogramsOncogenesPrognosisTumor MicroenvironmentCyclin-Dependent Kinase Inhibitor ProteinsDual-Specificity Phosphatases

Stichwörter der Autor:innen

AnoikisBioinformaticsLung adenocarcinomaPrognostic modelTumor immune microenvironment

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsCDKN3 protein, humanCyclin-Dependent Kinase Inhibitor ProteinsDual-Specificity Phosphatases

Autor:innen und Institutionen

  • National & Local Joint Engineering Research Center of Orthopaedic Biomaterials, Peking University Shenzhen Hospital, Shenzhen 518036, China; Shenzhen Key Laboratory of Orthopaedic Diseases and Biomaterials Research, She…
  • Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China.
  • Department of Oncology, Chaohu Hospital of Anhui Medical University, Hefei 238001, China.
  • Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: liujx0417@163.com.
  • Department of Radiology, Peking University Shenzhen Hospital, Shenzhen 518036, China. Electronic address: junyang@pkuszh.com.

Zitieren

APA

Qin, H., Wang, Q., Xu, J., Zeng, H., Liu, J., Yu, F., & Yang, J. (2024). Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma. International Immunopharmacology, 143, 113282. https://doi.org/10.1016/j.intimp.2024.113282

Vancouver

Qin H, Wang Q, Xu J, Zeng H, Liu J, Yu F, et al. Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma. International Immunopharmacology. 2024;143:113282. doi:10.1016/j.intimp.2024.113282

BibTeX
@article{Qin2024,
  author = {Qin, Haotian and Wang, Qichang and Xu, Juan and Zeng, Hui and Liu, Jixian and Yu, Fei and Yang, Jun},
  title = {Integrative analysis of anoikis-related genes prognostic signature with immunotherapy and identification of CDKN3 as a key oncogene in lung adenocarcinoma},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {143},
  pages = {113282},
  doi = {10.1016/j.intimp.2024.113282}
}
Kostenlos starten →